Skip to main content

Browse by Speciality Area

Browse by Product Type

All Products

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p>A new study concluded that the previously noted association between proton pump inhibitor use and community-acquired pneumonia is “likely to be due entirely to confounding factors.”</p>

PPI Use and Community-acquired Pneumonia Risks

December 8, 2016

Reprints

Related Articles

Proton pump inhibitor (PPI) use may not increase the risk of community-acquired pneumonia, according to a new study from researchers in the United Kingdom. In a cohort study spanning 1990-2013, 160,000 new PPI users were evaluated with three modalities: a multivariable Cox model comparing risk in PPI users with controls, a self-controlled case series, and a prior event rate ratio analysis over the 12-month periods before and after the first PPI prescription. The regression analysis showed a higher risk of pneumonia compared to controls (1.67 times higher for those exposed to PPI [95% confidence interval, 1.55-1.79]). But the other two analyses showed a lower risk. In the self-controlled study, the risk of pneumonia was almost twice as high in the 30 days prior to a PPI prescription (relative risk, 1.92; 95% confidence interval, 1.84-2.00). The prior event ratio also showed a higher risk of pneumonia the year prior to PPI use compared to the year after. The authors concluded that the previously noted association between PPI use and community-acquired pneumonia is “likely to be due entirely to confounding factors.” These factors may include gastroesophageal reflux disease. (BMJ 2016;355:i5813)